Firms & Funds

KKR raises $600 mln for healthcare growth equity fund

-
KKR, Kohlberg Kravis Roberts, healthcare, private equity, Slayback Pharma, pharmaceuticals
Stethoscope and $100 bills symbolizing healthcare spending and the affordable care act. Photo courtesy Photopa1/iStock/Getty Images
  • KKR healthcare fund heads for target
  • Led by Ali Satvat and Jim Momtazee
  • Recently invested in SlayBack Pharma

Kohlberg Kravis Roberts & Co’s healthcare fund has raised nearly $600 million, according to a regulatory filing.

The Form D lists about $334 million raised from third-party investors in KKR Health Care Strategic Growth Fund LP. Total commitments, including parallel vehicles and capital from the firm and its affiliates, equal about $598,5 million.

Bloomberg reported in September 2016 that the fund was targeting $650 million to $800 million.

KKR member Ali Satvat leads the firm’s healthcare strategic growth investing, and Jim Momtazee is head of the health care industry team. Both are based in Menlo Park, California.

In January, KKR closed a $60 million growth-equity investment in SlayBack Pharma, with Satvat joining the company’s board.

Slayback is the Princeton Junction, New Jersey, drug developer focused on products, the website says, that are “challenging and highly complex to develop and manufacture.”

Action Item: Ali Satvat’s bio on the KKR website: www.kkr.com/our-firm/leadership/ali-j-satvat

Photo courtesy Photopa1/iStock/Getty Images